AMW Pioneers Use of Artificial Intelligence in Formulation Development
25 February 2025
Warngau, February 25, 2025
AMW GmbH, a specialty pharmaceutical company focused on biodegradable controlled-release drug delivery systems, today announced the launch of a research and development project to optimize formulation development using…
AMW GmbH Appoints Additional Experts to its Scientific Advisory Board
01 July 2024
Warngau, Germany, July 1, 2024
AMW GmbH today announced the appointment of Prof. Miriam Breunig, Senior Academic Councillor at the University of Regensburg’s Department of Pharmaceutical Technology, and Prof. Karsten Mäder, Professor of…
AMW Again Reports Record Financial Results 2023, CEO Philipp Karbach Becomes Shareholder, Investment Program For Employees Launched
03 June 2024
Warngau, June 3, 2024
AMW GmbH, a specialty bio-pharmaceutical company focused on innovative sustained-release drug delivery systems, today reported financial results for the year ended December 31, 2023. AMW posted a 2023 consolidated record…
AMW Receives Notified Body Opinion by TÜV SÜD for its Leuprorelin Implant in Pre-Filled Syringe
15 May 2024
Warngau, Germany, May 15, 2024
AMW GmbH, a bio-pharmaceutical company specializing in innovative drug delivery systems, announced today that it has received the final Notified Body Opinion (NBO) report for its leuprorelin implant in prefilled…
AMW welcomes Ilse Aigner, President of the Bavarian State Parliament, at the Warngau site to share a success story
11 April 2024
Warngau, Germany, April 11, 2024
AMW GmbH, a specialty bio-pharmaceutical company focused on innovative sustained-release drug delivery systems, was delighted to welcome today the President of the Bavarian State Parliament, Ilse Aigner, to its…
AMW Further Strengthens Executive Leadership Team by Appointing Dr. Joerg Serafimov as Chief Business Officer
09 January 2024
Warngau, January 9, 2024
AMW GmbH, a specialty bio-pharmaceutical company focused on innovative sustained-release drug delivery systems, today announced that Dr. Joerg Serafimov has been appointed to the newly created role as Chief Business Officer…
AMW expands management team for strategic expansion course
28 November 2023
Sebastian Herzog as Chief Operating Officer responsible for Production, Quality, Supply Chain, Engineering, Operational Excellence and Logistics
Finance and IT under the new management of Matthias Dittmer
Warngau, November 28, 2023
…
AMW Receives first Notified Body Opinion by TÜV SÜD and Lays the Foundation for Further Approvals of Goserelin in the EU
09 August 2023
Warngau, August 9, 2023
AMW GmbH, a specialty pharmaceutical company focused on innovative sustained-release drug delivery systems, today announced that it has achieved a key milestone in opening new markets within the European Union (EU) and…
AMW reports financial results for fiscal 2022 and updates on corporate performance
11 April 2023
Record sales for fiscal year 2022 of €22.8 million
For the first time operating profitability achieved
Growth strategy secured by long-term financing of up to 30 million euros
Corporate development updates: Philipp Karbach becomes new CEO,…
AMW Appoints Professor Olivia Merkel to the Scientific Advisory Board
07 February 2023
Warngau, February 07, 2023
AMW GmbH, a specialty pharmaceutical company focused on innovative sustained-release drug delivery systems, today announced the appointment of Prof. Dr. Olivia Merkel, Professor for Drug Delivery in the Department of…
AMW and SAJA Pharmaceuticals sign license and supply agreement for commercialization of AMW’s goserelin implant
09 January 2023
Warngau and Jeddah, Kingdom of Saudi Arabia, January 9, 2023
AMW GmbH, a pharmaceutical company specializing in innovative drug delivery systems, and SAJA Pharmaceuticals, a leading regional drug manufacturer based in Jeddah, Saudi Arabia, with a…
Further EU Marketing Authorizations for AMW’s Leuprorelin Implant for the Treatment of Hormone-Sensitive Tumors
22 December 2022
Warngau, December 22, 2022
AMW GmbH, a specialty pharmaceutical company focused on innovative sustained-release drug delivery systems, today announced that its leuprorelin implant has received market authorization in two EU countries. Leuprorelin…
AMW and Mistral sign License and Supply Agreement for Commercialization of AMW’s Goserelin and Leuprorelin implants
25 October 2022
Warngau, Germany, and Coventry, Great Britain, October 25, 2022
AMW GmbH, a specialty pharmaceutical company focused on innovative sustained-release drug delivery systems, and Mistral Capital Management Ltd, a pharmaceutical company specialized in…
AMW Strengthens Management Team to Support the Company’s Growth Strategy
10 August 2022
Research & Development, Quality and Human Resources departments under new leadership of seasoned professionals
AMW GmbH, a specialty pharmaceutical company focused on innovative sustained-release drug delivery systems, today announced that it…
Further marketing approvals for AMW’s goserelin implant for the treatment of hormone-sensitive tumors in the EU and Central America
13 July 2022
AMW GmbH, a pharmaceutical company specializing in innovative drug delivery systems, announced today that its proprietary goserelin implant has received two additional marketing approvals in one country each in the European Union and Central…
AMW and AdhexPharma announce strategic partnership for transdermal delivery systems
09 November 2021
09.11.2021, Warngau / Chenôve
Strategic partnership in the field of transdermal delivery systems (TDS)
AMW to focus on its TDS development expertise and to broaden its pipeline on biodegradable slow-release implants
AdhexPharma to focus on TDS…
AMW signs license and supply agreements for the commercialization of its goserelin and leuprorelin implants in Israel
19 October 2021
-AMW grants your license to an undisclosed partner for the commercialization of its goserelin and leuprorelin implants in Israel -Increasing the availability of goserelin and leuprorelin for patients suffering from prostate cancer and breast…
AMW signs License and Supply Agreement for Commercialization of Goserelin Implant in a LATAM Country
22 May 2021
AMW grants license to undisclosed partner for commercialization of its goserelin implant in a LATAM country
Strengthening of availability of goserelin for patients suffering from prostate and breast cancer, as well as other indications as per…
AMW GmbH expands management team and appoints Dr. Konstantin Petropoulos as Chief Executive Officer
15 March 2021
Warngau, 15 March 2021
AMW GmbH announced today that Dr. Konstantin Petropoulos has been appointed Chief Executive Officer (CEO) effective March 15, 2021 This expands Dr. Friedrich Tegel and Philipp Karbach to the existing management team.
Dr.…
EMPLOYEES OF AMW DONATE THE PROCEEDS OF THE TOMBOLA IN THE AMOUNT OF 500 EURO
11 March 2021
Employees of AMW GmbH, a globally active pharmaceutical company based in Warngau, donate the proceeds from a tombola to Holzkirchen. The money was deliberately intended to benefit those in need here on the spot and so the choice was made on…
A thank you for the employees and region
29 December 2020
Santas deliver gifts by truck to the home office
First no company outing, then no Christmas party. Corona has also ruined beautiful traditions at the pharmaceutical developer AMW from Warngau. However, the company has created a replacement. Monday…
Expansion of the partnership between AMW and Zentiva for Western Europe
02 November 2020
Zentiva will include the leuprorelin implant to its portfolio for selected markets in Western Europe. This implant is another successful product of AMW, developed and produced by AMW The leuprorelin implant for the treatment of prostate cancer…
AMW GmbH realigns management
01 May 2020
Dr. Wilfried Fischer, founding shareholder of AMW, has retired from the management board.
He will remain associated with the company as an important shareholder. His areas of responsibility will be taken over by the previous Co-Managing Directors…